Gilead Sciences stock holds firm as revenue and cash flow stay strong

Published on 09/06/2026 at 19:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock is backed by a $28.2 billion revenue base and $7.1 billion in operating cash flow for the latest fiscal year, while the share price remains linked to the next batch of earnings signals.

Photorealistischer Biotech-Campus von Gilead Sciences mit Glaslabor und Wissenschaftlern — Gilead Sciences Forschungscampus mit ISIN US3755581036 modernes Biopharma-Labor Kalifornien Glasfassade Wissenschaftler arbeiten, Illustration mit AI erstellt.

Gilead Sciences stock (US3755581036) is anchored by $28.2 billion in revenue and $7.1 billion in operating cash flow for fiscal year 2025, two figures that still frame how the market values the drugmaker. Yahoo Finance carries the GILD quote page as of September 6, 2026.

Cash generation still matters

In fiscal year 2025, operating cash flow reached $7.1 billion, while revenue came in at $28.2 billion, giving investors a clear scale reference for the business. The comparison is concrete: cash flow covered roughly 25 percent of revenue in that period.

That matters because Gilead Sciences stock is rarely priced only on one quarter. The balance between antiviral demand, oncology growth and cash conversion is usually what shapes the next move.

Latest quarter in view

The most recent reported quarter available in the current research set was second quarter 2026, with revenue and EPS still the numbers to watch against the full-year base. The market typically compares that quarter with the prior-year period and the company's guidance path, not with older annual data.

For investors, the key point is the mix of current cash flow and reported growth. That combination tells more about the stock than a single headline number.

Go deeper

Gilead Sciences investor materials

The latest report and company background give context for revenue, cash flow and the next earnings step.

Open company page

Gilead Sciences stock and product focus

The company continues to lean on antiviral and oncology franchises, with Biktarvy and other core therapies still central to the business mix. That product concentration is why revenue quality and cash flow remain the main stock drivers.

Trading view

Gilead Sciences stock trades on NASDAQ under GILD. The market cap, quote, 52-week range and volume line should be read together with the latest reported cash flow and revenue base when the next trading session updates the picture.